Iradimed Corp (NASDAQ:IRMD) VP Brent Johnson Sells 1,000 Shares

Iradimed Corp (NASDAQ:IRMD) VP Brent Johnson sold 1,000 shares of the company’s stock in a transaction on Monday, August 12th. The stock was sold at an average price of $21.27, for a total transaction of $21,270.00. Following the completion of the transaction, the vice president now directly owns 2,368 shares in the company, valued at approximately $50,367.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Brent Johnson also recently made the following trade(s):

  • On Wednesday, August 14th, Brent Johnson sold 1,000 shares of Iradimed stock. The stock was sold at an average price of $21.10, for a total transaction of $21,100.00.
  • On Friday, August 9th, Brent Johnson sold 2,400 shares of Iradimed stock. The stock was sold at an average price of $21.81, for a total transaction of $52,344.00.
  • On Monday, August 5th, Brent Johnson sold 3,000 shares of Iradimed stock. The stock was sold at an average price of $21.94, for a total transaction of $65,820.00.
  • On Wednesday, August 7th, Brent Johnson sold 7,000 shares of Iradimed stock. The stock was sold at an average price of $21.93, for a total transaction of $153,510.00.
  • On Friday, August 2nd, Brent Johnson sold 5,000 shares of Iradimed stock. The stock was sold at an average price of $22.83, for a total transaction of $114,150.00.
  • On Wednesday, July 31st, Brent Johnson sold 8,000 shares of Iradimed stock. The stock was sold at an average price of $22.68, for a total transaction of $181,440.00.
  • On Monday, July 1st, Brent Johnson sold 1,000 shares of Iradimed stock. The shares were sold at an average price of $20.46, for a total value of $20,460.00.
  • On Wednesday, July 3rd, Brent Johnson sold 3,000 shares of Iradimed stock. The shares were sold at an average price of $20.16, for a total value of $60,480.00.
  • On Friday, June 28th, Brent Johnson sold 2,000 shares of Iradimed stock. The shares were sold at an average price of $20.53, for a total value of $41,060.00.
  • On Wednesday, June 26th, Brent Johnson sold 1,000 shares of Iradimed stock. The shares were sold at an average price of $20.34, for a total value of $20,340.00.

IRMD traded down $0.72 during trading on Wednesday, reaching $20.98. The stock had a trading volume of 50,628 shares, compared to its average volume of 70,909. The stock has a market capitalization of $238.54 million, a PE ratio of 48.79 and a beta of 1.65. The company has a current ratio of 10.29, a quick ratio of 9.39 and a debt-to-equity ratio of 0.06. Iradimed Corp has a one year low of $16.68 and a one year high of $38.78. The firm’s 50-day moving average is $19.95.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Oppenheimer Asset Management Inc. purchased a new stake in Iradimed during the first quarter valued at about $76,000. Victory Capital Management Inc. purchased a new stake in Iradimed during the first quarter valued at about $212,000. Charles Schwab Investment Management Inc. boosted its position in Iradimed by 34.0% during the second quarter. Charles Schwab Investment Management Inc. now owns 10,500 shares of the medical equipment provider’s stock valued at $215,000 after buying an additional 2,666 shares during the period. Marshall Wace LLP purchased a new stake in Iradimed during the first quarter valued at about $241,000. Finally, Morgan Stanley boosted its position in Iradimed by 14.3% during the second quarter. Morgan Stanley now owns 13,118 shares of the medical equipment provider’s stock valued at $268,000 after buying an additional 1,637 shares during the period. 23.49% of the stock is currently owned by institutional investors and hedge funds.

A number of research firms recently commented on IRMD. Zacks Investment Research cut Iradimed from a “buy” rating to a “hold” rating in a research note on Wednesday, July 3rd. BidaskClub cut Iradimed from a “buy” rating to a “hold” rating in a research note on Thursday, May 9th. Finally, ValuEngine raised Iradimed from a “sell” rating to a “hold” rating in a research note on Wednesday, July 31st. Three equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $31.50.

About Iradimed

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system.

Read More: Strangles

Insider Buying and Selling by Quarter for Iradimed (NASDAQ:IRMD)

Receive News & Ratings for Iradimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iradimed and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply